Babraham Bioscience Technologies “Technology Development Laboratory” (TDL) moves to Abzena - Abzena

Babraham Bioscience Technologies “Technology Development Laboratory” (TDL) moves to Abzena

Cambridge, UK, 5 January 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has entered into an agreement with Babraham Bioscience Technologies Limited (BBT), the company that manages and develops the Babraham Research Campus, to run and develop the services formerly provided by BBT’s Technology Development Laboratory (TDL).

This agreement allows a seamless transition of current projects, together with the capabilities, resources and expertise from TDL to Abzena. These capabilities include enzymatic assay development, small molecule inhibitor screening, molecular biology, cell culture and protein purification. These capabilities will integrate into Abzena’s existing broad range of solutions to support the progression of biopharmaceutical development from discovery through to manufacturing for clinical trials.

Abzena will also expand on TDL’s current antibody discovery capabilities to offers its clients a platform for the rapid generation of hybridoma cell lines expressing high affinity antibodies to their chosen target.

Campbell Bunce, SVP Scientific Operations, Abzena said:

“Bringing the expertise of the TDL scientists into Abzena and integrating them into our offering across biology and biomanufacturing aligns very well with our services and technologies as a solution provider for drug developers and augments the overall toolbox we can offer our customers. We look forward to building on the knowledge that the TDL team has brought and continuing an excellent working relationship with their current partners.”

Derek Jones, CEO, Babraham Bioscience Technologies said:

“We have had a long tradition in supplying this expertise from the TDL, but have experienced challenges in scaling up the services to provide an end-to-end solution to our customer base. We are pleased that these skills and expertise will be utilised and expanded by Abzena, particularly given that the capability will remain available at the Babraham Research Campus, as well as to the wider customer base.”

Enquiries:

Abzena plc

John Burt, Chief Executive Officer Julian Smith, Chief Financial Officer

Campbell Bunce, SVP Scientific Operations

Babraham Research Technologies Ltd

Derek Jones, Chief Executive Officer

+44 1223 903498

 

+44 1223 496000

Instinctif Partners

Melanie Toyne Sewell / Alex Shaw / Deborah Bell

+44 20 7457 2020

abzena@instinctif.com

Interested in our services? Get In Touch